Q-omics provides the consensus-scored MTCO1P20 profile across patient tissues and cancer cell-line models. MTCO1P20 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, MTCO1P20 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MTCO1P20 RNA expression shows 6,521 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, BRCA, and STAD as cancer lineages where MTCO1P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO1P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO1P20 survival associations across molecular data types. MTCO1P20 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO1P20 RNA expression–survival associations across cancer types. High MTCO1P20 expression shows unfavorable associations in TGCT, READ, UVM and LUAD, but favorable associations in CESC and UCS. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for MTCO1P20 RNA expression.
This table summarizes MTCO1P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO1P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO1P20 shows lower tumor expression in BRCA and LUSC and higher tumor expression in KIRC. The BRCA box plot shows higher MTCO1P20 RNA expression in normal versus tumor tissue (log2 FC = −0.077, t-test p = .001).
This table shows molecular features associated with MTCO1P20 in patient tissues and cancer cell lines. In patient samples, MTCO1P20 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
